ArticleAnnals of hematology2026
Bioinformatics-driven dissection of PANoptosis-related molecular subtypes and tumor immune microenvironment heterogeneity in pediatric acute myeloid leukemia.
Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PANoptosis, an integrated programmed cell death modality encompassing apoptosis, necroptosis, and pyroptosis, exerts pleiotropic effects on tumor immune surveillance and immune escape. However, the molecular mechanisms underlying PANoptosis in pediatric acute myeloid leukemia (AML) remain poorly elucidated. Here, we performed bioinformatic analyses of AML bone marrow transcriptomic data from the TARGET database, aiming to define PANoptosis-associated molecular subtypes, characterize tumor immune microenvironment (TIME) heterogeneity, and identify candidate regulatory genes and small-molecule binders. We identified 68 PANoptosis-related genes and used unsupervised clustering to resolve four molecular subtypes (C1-C4) with distinct clinical outcomes and TIME profiles. The C2 subtype exhibited robust CD8⁺ cytotoxic T-cell and natural killer (NK) cell activity linked to favorable prognosis, whereas the C1 subtype displayed immune suppression and poor survival. We identified an IGF1-CCL2-CCL4 gene set correlated with PANoptosis regulation and enriched in Toll-like receptor signaling. In silico molecular docking suggested SB216763 as a candidate ligand for these targets, though this requires experimental validation. Our findings outline PANoptosis-associated heterogeneity in pediatric AML and provide a stratification framework for future mechanistic and translational studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.